<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594152</url>
  </required_header>
  <id_info>
    <org_study_id>CHS#92-16</org_study_id>
    <nct_id>NCT00594152</nct_id>
  </id_info>
  <brief_title>Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)</brief_title>
  <official_title>Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators with the goal of optimizing glycemic and blood pressure control saw type 1
      diabetic patients weekly. A control group received 3-4 subcutaneous insulin injections per
      day; an intravenous insulin pulsed infusion group received, in addition, three one hour
      infusions in a pulsatile fashion over one eight hour period each week. Patients were followed
      for 12 months with periodic testing of renal function by repeated blood and urinary analyses;
      diabetes control by blood testing and diabetes impact measurement score; cardiac and
      autonomic function by echocardiography, 24 hour electrocardiographic testing; and visual
      changes with repeated fundus photography. The study hypothesis was that correction of
      respiratory quotient would correct the defect leading to microvascular complications of
      diabetes (Type 1).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1993</start_date>
  <completion_date type="Actual">January 1995</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of loss of creatinine clearance</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>12 to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac autonomic function</measure>
    <time_frame>12 to18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinal photos</measure>
    <time_frame>12 to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac function</measure>
    <time_frame>12 to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>1Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIIIT</intervention_name>
    <description>The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetics with proteinuria willing to be seen weekly for the evaluation of
             renal function

        Exclusion Criteria:

          -  Associated active medical diseases that would not permit evaluation of stable renal
             disease over 18 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A D'Elia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, Weinrauch LA, Weir M, D'Elia JA. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism. 2000 Nov;49(11):1491-5.</citation>
    <PMID>11092517</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>January 14, 2008</last_update_submitted>
  <last_update_submitted_qc>January 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>John D'Elia</name_title>
    <organization>Joslin Diabetes Center</organization>
  </responsible_party>
  <keyword>Diabetic autonomic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

